Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18518580 | 1.00 | FFAR1 (0.53) | FFAR1IDO1NAMPTCYP3A4ALDH1A1 | |
| SCHEMBL16977978 | 1.00 | FFAR1 (0.53) | FFAR1IDO1NAMPTCYP3A4ALDH1A1 | |
| SCHEMBL18518436 | 1.00 | FFAR1 (0.53) | FFAR1IDO1NAMPTCYP3A4ALDH1A1 | |
| SCHEMBL30455768 | 0.87 | NAMPT (0.44) | FFAR1IDO1NAMPTCYP3A4ALDH1A1 | |
| SCHEMBL30455741 | 0.87 | NAMPT (0.44) | FFAR1IDO1NAMPTCYP3A4ALDH1A1 | |
| SCHEMBL16977977 | 0.83 | NAMPT (0.45) | IDO1NAMPTCYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL439861 | 0.83 | NAMPT (0.45) | IDO1NAMPTCYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL25004996 | 0.81 | FFAR1 (0.55) | FFAR1ALDH1A1 | |
| SCHEMBL30181805 | 0.81 | FFAR1 (0.55) | FFAR1ALDH1A1 | |
| SCHEMBL23994457 | 0.81 | FFAR1 (0.55) | FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017025368-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-16 | — | — | WO | disclosed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | HRH2, HRH4, HRH3 | FFAR1 49/4885IDO1 301/4885NAMPT 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.